Venture
Capital for Nanotechnology and Microsystems
FIRST
QUARTER REPORT 2009
FELLOW
SHAREHOLDERS:
In the
2001 Letter to Shareholders (2001 Letter), we outlined our strategy for
investing in nanotechnology and microsystems, which at the time of the Letter we
referred to as “small-tech.” In the 2001 Letter we focused on three
points. First, we stated, “some observers believe that it is
difficult to identify any commercial product in future years and decades that
will not incorporate, be enhanced by, or made possible by small
tech. Nevertheless, our practical view as venture capitalists is that
small tech will become commercial in some fields long before others, which may
cause us to have industry clusters in our portfolio at any point in
time.” Second, we stated that “to even begin to capitalize on the
open-ended potential of small tech, we will have to grow the Company’s capacity
significantly.” Third, we said, “we believe that Harris & Harris
Group has significant corporate opportunity to create wealth for our
shareholders by investing in small tech.” Seven years have passed
since we outlined our strategy for investing in nanotechnology and microsystems,
and at the beginning of 2009 we re-visited the three points from the 2001 Letter
as a way to examine how Harris & Harris Group has developed over the past
seven years.
Our
evaluation of the first point from the 2001 Letter of whether nanotechnology was
living up to its potential to be incorporated into, enhance and make possible
new commercial products led us to write a white paper titled, "Why Invest in Nanotechnology? Harris
& Harris Group, Inc.'s Thesis." This paper was published
in Nanotechnology Law & Business in April 2009, and focused on four
important attributes of nanotechnology: new tools, new properties of materials,
additive manufacturing and nanoscale approaches to designing biological
pathways. The paper used examples from our portfolio companies to
describe how these four attributes of nanotechnology enable our portfolio
companies to make significant transitions in product capabilities within their
respective industries.
The
process of writing this paper focused our resolve that many new scientific and
technical breakthroughs occur through understanding and manipulating matter at
scales smaller than those that drove previous scientific and technical
breakthroughs. We continue to believe that one of the next
significant transitions in product capabilities will stem from understanding and
manipulating matter on the nanoscale and that this transition is well under
way. According to Lux Research, approximately $147 billion worth of
products incorporating nanotechnology were sold worldwide in 2007, and Lux
Research reports that the global marketplace for nanotechnology-enabled products
could reach $3.1 trillion by 2015. As we noted in the 2008 Annual
Letter to Shareholders, in 2008, the gross revenue for all our companies was
approximately $242 million, which was an increase of 22 percent from gross
revenue of approximately $198 million in 2007.
After
providing the foundation for our thesis of investing in nanotechnology, we
followed this first paper with two additional papers entitled, “Harris &
Harris Group Thesis for Investing in Nanotech for CleantechTM
Companies” and “Harris & Harris Group’s Approach to Investing in Nanotech
for HealthcareTM
Companies.” These papers address two of the first “industry clusters”
that have developed within our portfolio and why we believe nanotechnology is
important for these industries. Both papers develop the four
attributes of nanotechnology addressed in our first paper and also introduce 1)
the concept of new approaches to production and 2) the idea of the convergence
of multiple disciplines at the nanoscale. These papers again use
examples from our portfolio companies. All three papers can be
accessed on our recently updated web site, www.hhvc.com. The
papers can be found under the “Nanotechnology” heading where we also highlight
recently published articles on nanotechnology, cleantech and venture
capital.
Our
evaluation of the second point from the 2001 Letter led to an analysis of how we
have grown our capacity since 2001. At December 31, 2001, we had four
employees. We now have 11 employees. At December 31, 2001,
we had $24,334,770 in total net assets and our net asset value per share was
$2.75. At March 31, 2009, we had $109,215,327 in total net assets and
our net asset value per share was $4.22. At December 31, 2001, we had
$13,313,950 in U.S. Treasuries, net of outstanding debt. At March 31,
2009, we had $51,340,811 in U.S. Treasuries and no debt. At December
31, 2001, we had one active nanotechnology company and $489,999 invested in this
company. At March 31, 2009, we had 33 active companies in
nanotechnology and microsystems and $91,722,187 invested in these 33 active
companies. We have become a leader in investing in nanotechnology,
and we believe it is important to take the proper steps to maintain this
leadership position.
As to
point three from the 2001 Letter, we are aware that the real measure of our
investment strategy will be whether we create wealth for our shareholders by
investing in companies enabled by nanotechnology and
microsystems. Although NAV per share increased from $2.75 at December
31, 2001, to a historical high of $5.95 at June 30, 2008, before decreasing to
$4.22 at March 31, 2009, we have not realized significant exits or positive
returns from our nanotechnology and microsystems portfolio to
date. During the period from August 2001 through March 31, 2009, we
have invested a total of $105,137,888 in nanotechnology and microsystems
companies. We have realized $14,374,972 in losses, and $1,936,745 in
gains. As of March 31, 2009, we value the 33 active companies in our
portfolio at $58,791,835 versus a cost basis of $91,722,187. We
believe there are two primary reasons why we haven’t yet realized significant
exits. First, we invest in early-stage companies and these companies
often take many years to mature to the point where we can exit them through an
initial public offering (IPO) or through a merger or acquisition
(M&A). That is why most private venture capital funds are set up
as ten year partnerships. The average age of our current 33 active
nanotechnology and microsystems companies, from first dollar in, is 3.92
years. Second, in the past few years, it has been very difficult to
exit venture capital-backed companies through IPOs.
We see
three structural issues that could continue to hinder the venture capital
industry beyond the current recession. First, according to Dow Jones
VentureSource, the average time from investment to IPO or M&A has increased
to over nine years and over six years respectively. Second, we have
seen a dramatic decline in IPOs. According to Thomson Reuters and the
NVCA, from 1992 through 2000, 56 percent of successful venture capital exits
were IPOs and 44 percent were M&A transactions. From 2001 through
2008, only 13 percent of successful venture capital exits were IPOs and 87
percent were M&A transactions. Third, there has been a structural
shift in the IPO market. According to Dealogic, from 1991 through
1999, 80 percent of IPOs were transactions raising less than $50
million. From 2000 through 2008, only 20 percent of IPOs were
transactions raising less than $50 million. Clearly it takes more
time, more money and more mature companies to create exits in the current
environment.
Now that
we have examined our development over the past seven years, we believe it is
important to focus on the present. Currently, we face one of the most
difficult economic and venture environments of our generation. To
create value for our shareholders during these difficult times, we believe it is
important for management to be focused on three priorities. First, we
are focused on managing our portfolio, guiding our companies towards maturity,
and making difficult decisions about which companies to continue to finance, and
which companies not to finance. Shareholders should expect us not to
continue financing all our companies, and even to realize losses on companies we
do not believe can be successful in the current economic
environment. Historically, we have lost money in over 60 percent of
our realized investments even though we have returned $143,923,354 on invested
capital of $60,549,559 in these realized investments. As portfolio
managers, it is important for us to recognize the winners and the losers in our
portfolio as early as possible and, in the parlance of venture capital, to “feed
the fat hogs and starve the lean ones.”
Second,
we are focused on managing our current capital. For example, as we discussed on
page 36 of our Quarterly Report on Form 10-Q for the period ending March 31,
2009, even with a decrease in investment income of $599,863 during the first
quarter of 2009 as compared to the first quarter of 2008, primarily owing to a
dramatic decrease in the yield of treasuries, our net operating loss decreased
from $2,480,618 at March 31, 2008, to $2,098,879 at March 31,
2009. One component of net operating loss, “salaries, benefits and
stock-based compensation,” decreased by $1,045,955, or 42.9 percent through
March 31, 2009, as compared to March 31, 2008. Removing the expense
related to stock-based compensation of $635,638 for the first quarter of 2009
and $1,466,960 for the first quarter of 2008, which does not impact our net
asset value per share, results in a decrease in salaries and benefits of
$214,613, or 22.2 percent through March 31, 2009, as compared to March 31,
2008. It is important to manage our capital so that we have capital
available to: 1) make follow-on investments in our most promising
portfolio companies and 2) invest in promising public and private
nanotechnology-enabled companies that are currently raising money at
historically low valuations. Our deal flow continues to be robust,
and we believe many of the nanotechnology-enabled companies that can
successfully raise money at the current valuations, and in the current
environment, have a chance to provide potential investment returns in the
future.
Third, we
are focused on positioning our portfolio companies for potential exit
opportunities that we believe may be possible even without a strong recovery of
the venture-backed IPO market.
Although
much of our time is focused on managing Harris & Harris Group through the
current economic environment, we believe it is also important to look forward
and to position ourselves for the future. On April 20, 2009, the New
Yorker published an article by James Surowiecki entitled “Hanging
Tough.” The article describes the dominance of short-term
considerations over long-term potential in the thinking of business leaders
during a recession. In a recession companies worry more about
failures resulting from making a bad bet rather than from failures resulting
from letting a great opportunity pass. Because most companies are
focused on not “sinking the ship,” they “miss the boat” on opportunities that
present themselves. Jack and Suzy Welch said it best in their weekly
opinion column in Business Week, “… there is one defining aspect of leadership
that you cannot, must not, neglect in the craziness of the
morass: Inventing the future.”
We
believe management of Harris & Harris Group must stay focused on “inventing
the future” during these times. However, as a venture capital firm
focused on nanotechnology, it is our portfolio companies that do the majority of
the inventing of the future. Through this downturn, that is what many
of our portfolio companies continue to do. Over the past few
quarters, a number of our portfolio companies have made announcements concerning
their commercial progress. Below we provide a sampling of these
announcements:
-
|
In
May 2009, Crystal-IS announced a memorandum of understanding for a joint
development agreement with Sanan Optoelectronics, a significant
manufacturer of full-color LEDs in
China.
|
-
|
In
April 2009, Ensemble announced a strategic alliance with Bristol-Myers
Squibb to develop a novel set of drug
candidates.
|
-
|
In
April 2009, BioVex announced that it commenced Phase III clinical trials
in metastatic melanoma.
|
-
|
In
April 2009, Solazyme announced that a study undertaken by Life Cycle
Associates, LLC, using the Argonne National Laboratories GREET model,
concluded that full lifecycle greenhouse gas (GHG) emissions from
field-to-wheels for Solazyme's algal biofuel, SoladieselTM,
are 85 to 93 percent lower than standard petroleum based ultra-low sulfur
diesel (ULSD). The analysis also reveals that Solazyme's
advanced biofuels result in a significantly lower carbon footprint than
any currently available first-generation
biofuels.
|
-
|
In
March 2009, NeoPhotonics received the top product and customer support
quality award from Huawei. This award celebrates NeoPhotonics'
excellence in components for Huawei’s access, metro and long-haul optical
network equipment.
|
-
|
In
January 2009, Cambrios entered into a joint partnership with Sumitomo
Corporation and Chisso Corporation to commercialize transparent conductive
material for TFT-LCDs.
|
-
|
In
January 2009, Innovalight and Roth & Ray AG of Germany completed the
installation of what we believe is the first silicon ink-based solar cell
pilot production facility.
|
-
|
In
January 2009, Bridgelux introduced its 400-2000 lumen LED array product
developed to provide lamp and luminaire manufacturers with a solution that
reduces system cost.
|
-
|
In
October 2008, Kovio launched what we believe is the first silicon
ink-based RFID tag.
|
-
|
In
the second half of 2008, Metabolon announced multiple partnerships,
including the expansion of its agreement with Syngenta and a partnership
with LS9 for biofuel research and
development.
|
Although
it is a very difficult time for venture-backed companies, many of our portfolio
companies continue to execute on their business plans and continue to make
progress on bringing their nanotechnology-enabled products to
market.
To
conclude, we began 2009 re-visiting our focus on investing in companies enabled
by nanotechnology and microsystems. This exercise led us to reaffirm
our commitment to this investment thesis and to re-confirm our closing words
from the 2001 Letter that “now is the time to act.” Our companies are
working in areas that will permit one of the next significant transitions in
product capabilities. Our companies are working in “industry
clusters” towards which the market has shown excitement. Our deal
flow has strengthened in each successive year since 2001. Management
continues to come to work each day believing that we are in the process of
creating wealth for our shareholders. In the 2001 Letter, in addition
to the three points mentioned earlier, we also said that at the 2002 Annual
Meeting of Shareholders, shareholders would be asked “to change the name of the
Company to Small-Technology Venture Capital, Inc.” Sometimes it is
the smallest decisions that make a difference. I don’t know if it was
luck or prescience, but thankfully, we made the right decision by maintaining
the name Harris & Harris Group, Inc., as the credibility and goodwill it
carries will be critical to our success.
|
|
|
|
Douglas
W. Jamison
|
Daniel
B. Wolfe
|
Chairman
and Chief Executive Officer
|
President
and Chief Operating Officer
|
Managing
Director
|
Chief
Financial Officer Managing Director
|
|
|
|
|
|
|
|
|
Michael
A. Janse
|
Alexei
A. Andreev
|
Executive
Vice President
|
Executive
Vice President
|
Managing
Director
|
Managing
Director
|
May
18, 2009
|
This
letter may contain statements of a forward-looking nature relating to
future events. These forward-looking statements are subject to the
inherent uncertainties in predicting future results and
conditions. These statements reflect the Company's current
beliefs, and a number of important factors could cause actual results to
differ materially from those expressed in this letter. Please
see the Company's Annual Report on Form 10-K for the year ended December
31, 2008, the Company's report on Form 10-Q for the quarter ended March
31, 2009 and subsequent SEC filings, filed with the Securities and
Exchange Commission for a more detailed discussion of the risks and
uncertainties associated with the Company's business, including but not
limited to the risks and uncertainties associated with venture capital
investing and other significant factors that could affect the Company's
actual results. Except as otherwise required by Federal
securities laws, Harris & Harris Group, Inc., undertakes no obligation
to update or revise these forward-looking statements to reflect new events
or uncertainties. The reference to the website www.HHVC.com has
been provided as a convenience, and the information contained on such
website is not incorporated by reference into this letter.
|